Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Gynecologic Oncology
•
Endometrial Cancer
How does positive peritoneal washings factor into your treatment decisions regarding pelvic radiation and/or chemotherapy?
For example, in an otherwise intermediate risk localized endometrial cancer (Grade 2, FIGO IB)?
Answer from: Radiation Oncologist at Community Practice
At this point, for patients who lack other adverse factors, we do not change management based on positive cytology for endometrioid histology.
Sign in or Register to read more
1106
Related Questions
How do you manage a FIGO stage IB dedifferentiated endometrial carcinoma that is MMR deficient and p53 wt?
Would you treat with extended field pelvic radiation for a patient with FIGO IIIC1 endometrial cancer who was found with isolated tumor cells (ITCs) on a single paraaortic sentinel lymph node?
Given the negative results of GOG-0238 but the positive results of the RUBY trial, how do you manage isolated vaginal cuff recurrence of endometrial cancer?
How would you sequence adjuvant chemo-immunotherapy (paclitaxel/carbo/pembro or paclitaxel/carbo/dostarlimab) with EBRT and vaginal cuff brachytherapy in advanced uterine cancer that meets clinical criteria for both EBRT and chemo-IO?
What adjuvant treatment would you recommend for a patient with FIGO 2023 IIIB2 endometrioid endometrial adenocarcinoma (Grade 3, p53mut, MMR proficient), metastatic to the uterine serosa, bilateral ovaries, and anterior peritoneal reflection?
How would you treat recurrent endometrial carcinoma with a presentation of inguinal and external iliac adenopathy?
How would you manage a POLE mutated, p53 abnormal IA myoinvasive carcinosarcoma of the endometrium with no LVSI?
How do you classify extensive LVSI in endometrial cancer?
What are your top takeaways in Gyn Cancers from ASCO 2024?
How would you manage a cervical cancer patient with bulky PA LNs with direct extension and/or invasion into the lumbar vertebral bodies?